{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457119389
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[interferon gamma]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 326859-36-3
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6J92H2439Z
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04242
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight = ca. 150 kg/mol
}}
'''Fontolizumab''' (planned trade name '''HuZAF''') is a [[humanized monoclonal antibody]]<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/fontolizumab.doc Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab], ''American Medical Association''.</ref> and an [[immunosuppressive drug]] for the treatment of [[auto-immune disease]]s like [[Crohn's disease]].<ref>{{cite journal|pmid=19637334|year=2009|last1=Reinisch|first1=W|last2=De Villiers|first2=W|last3=Bene|first3=L|last4=Simon|first4=L|last5=Rácz|first5=I|last6=Katz|first6=S|last7=Altorjay|first7=I|last8=Feagan|first8=B|last9=Riff|first9=D|last10=Bernstein|first10=Charles N.|last11=Hommes|first11=Daniel|last12=Rutgeerts|first12=Paul|last13=Cortot|first13=Antoine|last14=Gaspari|first14=Michael|last15=Cheng|first15=May|last16=Pearce|first16=Tillman|last17=Sands|first17=Bruce E.|title=Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study|doi=10.1002/ibd.21038|journal=Inflammatory bowel diseases|pages=233–42|volume=16|issue=2|display-authors=8}}</ref> A phase II [[clinical trial]] investigating the use for [[rheumatoid arthritis]] was terminated because the first phase did not meet the [[clinical endpoint|endpoint]].<ref>{{ClinicalTrialsGov|NCT00281294|A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis}}</ref>

== References ==
<references/>


{{Immunosuppressants}}
{{Monoclonals for immune system}}
{{Cytokine receptor modulators}}

[[Category:Monoclonal antibodies]]
[[Category:Abandoned drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}